The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Novel cannabinoid receptors
Open accessAbstract
Cannabinoids have numerous physiological effects. In the years since the molecular identification of the G protein‐coupled receptors CB 1 and CB 2, the ion channel TRPV 1, and their corresponding endogenous ligand systems, many cannabinoid‐evoked actions have been shown conclusively to be mediated by one of these specific receptor targets. However, there remain several examples where these classical cannabinoid receptors do not explain observed pharmacology. Studies using mice genetically deleted for the known receptors have confirmed the existence of additional targets, which have come to be known collectively as non‐CB 1/CB 2 receptors. Despite intense research efforts, the molecular identity of these non‐CB 1/CB 2 receptors remains for the most part unclear. Two orphan G protein‐coupled receptors have recently been implicated as novel cannabinoid receptors; these are GPR119, which has been proposed as a receptor for oleoylethanolamide, and GPR55 which has been proposed as a receptor activated by multiple different cannabinoid ligands. In this review I will present an introduction to non‐CB 1/CB 2 pharmacology, summarize information on GPR55 and GPR119 currently available, and consider their phylogenetic origin and what aspects of non‐CB 1/CB 2 pharmacology, if any, they help explain. British Journal of Pharmacology (2007) 152, 567–575; doi:10.1038/sj.bjp.0707481; published online 1 October 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
Haller, J., Varga, B., Ledent, C., & Freund, T. F. (2004) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000135704.56422.40 · Cited by 241 · cited 1×
“Hints about the role of hippocampal non-CB1/CB2 receptors have come from the demonstration that SR141716A but not AM251 has anxiolytic effects in CB1 / mice, hence the non-CB1/CB2 site might mediate anxiogenesis, opposing the anxiolytic effects of CB1 (Haller et al., 2004).”
Background
Cited by
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Metadata
- Authors
- Brown, A. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 567-575
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1824285398
- Cited by
- 409
- References
- 4
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel cannabinoid receptors. https://app.cochat.ai/papers/10.1038/sj.bjp.0707481
- The paper
- Brown, A. J. (2007). Novel cannabinoid receptors. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.